TURSI, A.; TIANO, M. SARS-COV-2 infection might cause transient cutaneous lesions in IBD patients under treatment with adalimumab. Journal of Gastrointestinal and Liver Diseases, v. 30, n. 2, p. 310-311, 19 jun. 2021.